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INTRODUCTION 
 
 “He who really understands what is involved in the breathing of man, 
has already sensed the breath of God”1.       
 Asthma is a serious global health problem, affects people of all ages, in 
all parts of the world. Despite greatly increasing knowledge of the immuno 
pathological processes, characteristics of the disease and apparent 
improvements in treatment, morbidity is increasing rather than decreasing. 
 There is now great potential for improving the management of 
asthmatic patients by encouraging more rational use of treatments already in 
existence. The Global initiative for Asthma (GINA) was implemented to 
develop a network of individuals, organizations, and public health officials to 
disseminate information about the care of patients with asthma while at the 
same time assuring a mechanism to incorporate the result of scientific 
investigations into asthma care2. 
 A greater number of clinicians are now aware of these management 
recommendations. A world wide unified approach to the management of 
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asthma would be ideal. But this approach is not feasible because of inter 
country socioeconomic variables and the financial burden of therapy, which 
will be too heavy for some of the resource poor settings. 
 There are similarities in the treatment of asthma and diabetes, since in 
both diseases the aim is to allow the patient to be as independent as possible 
and to make treatment changes as appropriate to maintain clinical control. 
However, patients should get professional advice whenever self-management 
has not been successful. Moreover, patients contact their health care 
professionals for review and advice periodically (or) as and when required. 
The principles of management in general are to 
 Recognize asthma, 
 Abolish Symptoms, 
 Restore normal (or) best possible long term airway function, 
 Reduce the risk of severe attacks, 
 Enable normal growth to occur in children, and 
 Minimize absence from school (or) work. 
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The other aspects to be considered in the management are 
 Patient and family participation, 
 Avoidance of identified causes where ever possible, and 
 Use of lowest effective doses of convenient medications minimizing 
short-term and long-term side effects3. 
 In general, allow all the patients to lead good quality of life without 
symptoms, free from side effects of drugs, adjusted and modified by patient 
involvement. 
 Drug therapy for asthma includes those that inhibit smooth muscle 
contraction (beta adrenergic agonist, methyl xanthines, anticholinergics) and 
agents that prevent (or) reverse inflammation (glucocorticoids, mast cell 
stabilizers and leukotriene modifiers) 4. 
 Salbutamol, a short acting, selective beta-2 adrenoreceptor agonist is 
one of the most commonly used bronchodilators in the treatment of reversible 
airway obstruction5. Salbutamol is included in Essential drug list 6 (WHO List 
22.5). 
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 Salbutamol has been marketed as a racemic mixture, although beta-2 
agonist activity resides almost exclusively in the (R)-enantiomer.7 It is an 
active enantiomer of racemic salbatamol while the (S)-enantiomer is inactive 
and this may be associated with airway hyper reactivity and has more adverse 
effects.8,9 Hence, research was focused to develop an enantiomerically pure 
(R)–salbutamol known as Levosalbutamol, which has been documented, as 
more efficacious and without potential unfavourable effect than racemic 
salbutamol in enhancing airflow of patients with bronchospasm. 10,11  Several 
drugs are now being marketed or being developed as single enantiomers in 
place of a previous racemic mixture, a process known as chiral ‘Switching’ 
or Racemic ‘Switching’12,13.   Levosalbutamol is one such molecule. 14,15 
Published reports state that levosalbutamol a molecule approved in 
2004 for regular use has better effect then racemic form. However, not much 
studies made on the usefulness of levosalbutamol from south India. Hence the 
present study is undertaken to assess the efficacy of levosalbutamol compared 
to racemic salbutamol in patients with bronchial asthma. 
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AIM OF THE STUDY 
 
1. To compare the efficacy and tolerability of Racemic salbutamol and  
Levosalbutamol  
 
2. To identify the side effects of each, and to recommend the appropriate one. 
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REVIEW OF LITERATURE 
Etymology 
 Asthma is an ancient Greek word meaning “Panting (or) short drawn 
breath”  which might has probably derived from the word ‘azo’. The word azo 
means breath hard. It was called as in middle English “asma” derived from 
medieval Latin, a modification of Greek asthma. 
Bronchial asthma in Ayurveda16 
 In Ayurveda, and Indian system of medicine the disease is termed as 
“shwasa” in general and it has classified this disease into further five subtypes 
of which one is ‘Tamakashwasa’, which shows a great similarity in its 
symptomatology with bronchial asthma.  
Bronchial asthma in Siddha 17 
 In siddha , an ancient Tamil medicine, the disease Asthma is described 
as Iraippu Nooi ,Eluppu nooi ,suvasa kasam 
In International Code for Diseases the Number for Asthma is given as (ICD-
9CM CODES WHO 9th edition)  
493.9- Asthma, unspecified 
493.1- Intrinsic Asthma 
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493.0- Extrinsic Asthma 
Definitions of Asthma 18,19 
 Based on the functional consequences of airway inflammation, an 
operational description of asthma is that: 
 Asthma is a chronic inflammatory disorder of the airways in which 
many cells and cellular elements play a role. The chronic inflammation causes 
an associated increase in airway hyper responsiveness that leads to recurrent 
episodes of wheezing, breathlessness, chest tightness, and coughing, 
particularly at night (or) in the early morning. These episodes are usually 
associated with widespread but variable airflow obstruction that is often 
reversible either spontaneously (or) with treatment. 
 Asthma is defined by the American thoracic society [124] as a disease 
characterized by an increased responsiveness of the trachea and bronchi to 
various stimuli manifested by a widespread narrowing of the airways that 
changes in severity either spontaneously (or) as a result of therapy. 
Historical development of Adrenergic Agonists20 
 Airway regulation involves both the sympathetic (adrenergic) and 
parasympathetic (cholinergic) autonomic nervous system. In response to 
stress, allergic reactions (or) physical activity the neurotransmitters               
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norepinephrine and epinephrine are released. Epinephrine is a powerful 
bronchodilator and vasopressor. Many of the currently used adrenergic agonist 
bronchodilators are structurally related to epinephrine. 
Ancient folk medicine 
18th century 
- Inhalation of smoke from the burning of variety of 
solanaceous plants including. Atropa belladonna 
(deadly night shade), Hyosyamus niger (black hen 
bane), Datura stramonium (Jimson weed, Jamestown 
weed (or) thorn apple) 
1895 - Extract of sheep adrenal gland Intravenously for 
Vasopressor effect reported by Oliver and Shafer. 
Abel-who named it epinephrine, Takamine - who 
called it adrenaline. 
1904 - Aldrich - identified the correct empirical formula for 
epinephrine C9H13NO3 - and synthesised the 
compound independently 
1910 - The term sympathomimetics was introduced Barger 
and dale investigated the pharmacological activity of 
a number of synthetic amines structurally related to 
epinephrine. 
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Epinephrine - Derived from the Chinese herbal medicine Mahuang 
(Ephedra vulgaris) Employed  for many years as a 
treatment for bronchial asthma first orally effective 
adrenergic bronchodilator 
1924 - Chen and Schmidt isolated the active substance and 
described the physiological effects 
1930 - Ephedrine as bronchodilator through the 1930. 
1940 - Substitution of methylgroup of epinephrine lead to 
ephedrine Konzett observed N- isoprophyl derivative 
of epinephrine (isoprenaline, isoproterenol) 
1948 - Ahlquist identified alpha & beta receptors. 
1960s and 1970s - Large number of β2 selective bronchodilators were 
developed during 1960s & 1970s. Allen and 
Hanburys developed a compound salbutamol by 
replacing the side chain of isoproterenol by tert-butyl 
group replacing Isopropyl group of Metaproterenol 
with tert-butyl group terbutaline is prepared 
Additional enlargement of the side- chain amino 
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function of Metaproterenol, Fenoterol was prepared 
by Bochringer Ingelhein 
To minimize 
vasodilatation and 
cardiac side effects 
additional drugs were 
investigated 
- Examples of compounds brought to various  stages 
of development, including marketing approval are 
solterenol, salmefamol, carbuterol, denbuterol, 
rimiterol, mabuterol, pirbuterol, quinterenol, 
procaterol and broxaterol 
Approaches to longer 
acting bronchodilators 
- Bitolterol, Bambuterol (Prodrug of terbutaline) 
Newer aerosol drugs - Formoterol and Salmeterol 
List of Drugs during 1994 – 2004 
S.No 
Date of Approval 
from FDA, (USA) 
Name of the Drug 
Pharmacological 
Classification 
215 16-07-2004 Levosalbutamol tablet    
1mg/2mg & syrup 1mg/5ml 
For obstructive 
diseases 
 
Document type – New Drug Profile 
Affiliations : 1: Adis International Limited, Auckland, New Zealand 
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ETIOLOGY 21,22 
 
 Asthma cannot be cured, but could be controlled. The strongest risk 
factors for developing asthma are genetically susceptible host, allergens, 
respiratory infections, and certain occupational and environmental stimuli.  
Once the inflammation and bronchial hyper reactivity are present, can be 
triggered by additional factors, including exercise, inhalation of cold, dry air, 
cigarette smoke, physical (or) emotional stress, inhalation of irritants, 
pharmacological agents such as, NSAIDS and beta blockers, methacholine 
and histamine, respiratory infections ( viral / bacterial ),and allergens. 
Allergens 
a. Ingested ( fish, nuts, strawberries) 
b. Inhaled ( Dust, Pollen, house dust mite ) 
c. Food additives (tartazine, ajinomoto) 
d. Occupational allergens ( grain dust, wood dust)   
 
EPIDEMIOLOGY 23,24 
  The prevalence of asthma is rising in most parts of the world.  It is 
estimated that 4-5% of the population of United States is affected. Data from 
the centers for disease control and prevention suggest that 10 to 11 million 
persons had acute attacks in 1998.  It has varied considerably within countries. 
It is more prevalent in developed countries than developing ones.  In India, 
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prevalence of asthma has been found to be around 6% in the majority of 
surveys.  However, it has been reported to vary from 2 to 17% in different 
study population.  The disease can start at any age, but in a majority, it starts 
before 10 years of age.  It is twice as common amongst boys than girls, where 
as in adults the Male-Female ratio is usually equal. 
 
The scale of the problem in different developed countries are provided 
below: Table 125 
Between 100 and 150 million people around the globe, roughly the 
equivalent of the population of the Russian Federation, suffer from asthma and 
this number is rising. World-wide, deaths from this condition have reached 
over 180,000 annually. 
TABLE 1: SCALE OF THE PROBLEM IN DIFFERENT COUNTRIES 
Country Percentage of Asthma 
1. Swiss 8% (2%-25-30years) 
2. US 60%(1980s) 
3. Japan 7%(severe), 30% (moderate) 
4. Caroline Islands 50%(children) 
5. Brazil, Costa Rica, Panama, Peru,  
    Uruguay 
20-30%(children) 
6. Kenya 20% 
7. India 10-15% 
8. Papua New Guinea 0% 
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The human and economic burden 
 Mortality due to asthma is not comparable in size to the day-to-day 
effects of the disease. Although largely avoidable, asthma tends to occur in 
epidemics and affects young people. The human and economic burden 
associated with this condition is severe. The costs of asthma to society could 
be reduced to a large extent through concerted international and national 
action. 
World-wide, the economic costs associated with asthma are estimated 
to exceed those of TB and HIV/AIDS combined.  
In the United States, for example, annual asthma care costs (direct and 
indirect) exceed US$6 billion.  
At present Britain spends about US$1.8 billion on health care for 
asthma and because of days lost through illness.  
In Australia, annual direct and indirect medical costs associated with asthma 
reach almost US$460 million. 
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PATHOPHYSIOLOGY 18,26,27 
Gross appearance 
 Patients dying from acute episodes of asthma have bulky over 
distended lungs which fail to deflate when chest is opened.  The airways are 
thickened and plugged with secretions. 
Microscopic appearance 
 The main feature of asthmatic airways are marked thickening of 
basement membrane, bronchial smooth muscle hypertrophy and damaged 
epithelium, much of which is shed.  The bronchial wall contains the 
inflammatory cells, frequent and characteristic being eosinophils.  Other cells 
include neutrophilis, lymphocytes, mast cells and plasma cells.  The mucus or 
bronchial secretions of an asthmatic patient contains eosinophils, desquamated 
airway epithelial cells termed creola bodies, charcot leydon crystals and thick 
thread like sputum called curshman’s spirals. 
 
 15
IMMUNOLOGICAL ASPECTS OF ASTHMA 28,29 
Early phase reaction 
 Antigen absorption occurs from the mucus membrane, gut, respiratory 
tract or skin.  These antigens combine with human proteins and this foreign 
protein or complex comes into contact with macrophages on the mucosal 
linings or in regional lymph nodes and is “processed” by these cells.  Either 
the processed antigen itself or a message from macrophages stimulates          
B-Lymphocytes produce antigen-specific IgE. The amount of IgE produced 
depends on the antigen dose, the route of antigen exposure, the number of 
allergenic sites on the antigenic proteins, and the genetic makeup of the host.  
In several experimental situations where suppressor T-Cell activity is 
suppressed, produced increased IgE. Several cell types have surface IgE 
receptors including basophils, macrophages, mast cells, eosinophils, platelets 
and lymphocytes.  The IgE antibody molecules attached to the cell surface 
initiate an IgE mediated reaction. 
 The antigen – antibody reaction on the cell surface elicits intracellular 
events.  In general, the outcome of these intracellular calcium and adenosine 
 16
triphosphate dependent events release of various mediators.  The classical 
mediator released by allergic reactions is histamine, which directly causes 
bronchial smooth muscle contraction and stimulates reflex bronchospasm. 
 Eosinophilic chemotactic factor of anaphylaxis is another preformed 
mediator, and metabolites such as prostaglandins, thromboxanes, Leukotriene, 
platelet activating factor (PAF) likely to play important role in asthma, 
especially in chronic asthma and late-phase inflammatory reactions. In 
addition to their immediate effect on smooth muscle, these potent mediators 
initiate chemotaxis and increased vascular permeability. 
Late-Phase Allergic Reaction  
This allergic response is characterized by inflammation, edema, 
bronchoconstriction, and occasional symptoms of fever and malaise.  It 
follows the early response by 4 to 8 hours, without the early response the later 
one does not occur.   PAF, often released from eosinophils  has potent 
inflammatory activity and has been associated with the production of airway 
hyper reactivity  by producing vascular permeability and edema. 
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DIAGNOSIS OF ASTHMA2,3,30  
• Asthma is under diagnosed throughout the world. 
• Asthma can often be diagnosed on the basis of symptoms such as 
episodic breathlessness, wheezing and chest tightness. Seasonal 
variability of symptoms and a positive family history of asthma and 
atopic disease also helps as diagnostic guides. 
• However, measurements of lung function, and particularly the 
reversibility of lung function abnormalities greatly enhance diagnostic 
confidence. 
• Lung function measurements that are most helpful for the diagnosis of 
asthma (in patients over 5 years of age) include forced expiratory 
volume in 1 second (FEV1) forced vital capacity (FVC), peak 
expiratory flow (PEF), and airway hyper responsiveness.  Among them 
Peak expiratory flow meter (PEFM) is commonly used in most of the 
places. 
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• Measurement of symptoms and lung function are important parameters 
for assessing the characteristic of the patient’s asthma. 
Symptoms that are useful when considering a diagnosis of asthma 
- attack or recurrent attacks of wheezing 
- troublesome cough at night 
- Wheeze or cough, chest tightness after exposure to airborne allergens 
or pollutants 
- Colds “go to the chest” or take more than 10 days to clear up 
      -    Symptoms improvement after antiasthma treatment 
International Union Against Tuberculosis and Lung disease (IUATLD) 
Asthma Questionnaire2,31 
 Have you had Wheezing or Whistling in your chest at any time? 
 Have you had an attack of shortness of breath that came on 
following strenuous activity at any time? 
 Have you woken up with an attack of wheezing at any time? 
 Have you woken up with an attack of coughing at any time? 
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 Have you had an attack of shortness of breath that came on 
during the day when you were at rest at any time? 
All these things were considered during the selection of cases for the 
study. 
 
Physical Examination 21,22 
 Because asthma symptoms are variable, the physical examination of the 
respiratory system may be normal.  The most usual abnormal physical finding 
is wheezing on auscultation.  However, some people with asthma have normal 
auscultation but significant airflow limitation when measured objectively. 
 Clinical signs such as dyspnoea, airflow limitation (wheeze) and      
hyperinflation are more likely to be present if patients are examined during 
symptomatic periods.  The combination of hyperinflation and advanced 
airflow limitation in an asthma exacerbation also markedly increases the work 
of breathing.  Although wheezing is the most typical physical finding in 
asthma, the sign may be absent in severe asthma exacerbations.  However, 
patients in this state usually have other physical signs reflecting severity, such 
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as cyanosis, drowsiness, difficulty in speaking, tachycardia, hyper inflated 
chest, use of accessory muscles, and intercostals recession.32  The 
classification of severity of asthma exacerbations  is provided in table 2. 
TABLE 2: CLASSIFICATION OF SEVERITY OF ASTHMA 
EXACERBATIONS * 
 
 Mild Moderate Severe 
Impending 
Respiratory 
Failure 
Symptoms 
 
Breathlessness 
 
Speech 
 
 
With activity 
 
Sentences 
 
 
With talking 
 
Phrases 
 
 
At rest 
 
Words 
 
 
At rest 
 
Mute 
Signs 
 
Body position 
 
 
Respiratory rate 
 
Use of accessory 
respiratory muscles 
 
Breath sounds 
 
 
 
 
 
Heart rate (beats/min) 
 
 
Pulsus paradoxus  
(mm Hg) 
 
Mental status 
 
 
Able to 
recline 
 
Increased 
 
Usually not 
 
 
Moderate 
wheezing 
At mid-to-
end-
expiration 
 
<100 
 
 
<10 
 
 
May be 
agitated  
 
 
Prefers 
sitting 
 
Increased 
 
Commonly 
 
 
Loud 
wheezes 
throughout 
expiration 
 
 
100 – 120 
 
 
10-25 
 
 
Usually 
agitated 
 
 
Unable to recline 
 
 
Often > 30/min 
 
Usually 
 
 
Loud inspiratory and 
expiratory wheezes 
 
 
 
 
>120 
 
 
Often > 25 
 
 
Usually agitated 
 
 
Unable to recline 
 
 
> 30 /min 
 
Paradoxical 
thoracoabdominal 
movement 
Little air 
movement 
without wheezes 
 
 
 
Relative 
bradycardia 
 
Often absent 
 
 
Confused or 
drowsy 
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Functional 
assessment 
 
PEF(% predicted or 
personal best) 
 
Sa02(%, room air) 
 
Pa02(mm Hg, room 
air) 
 
PaC02(mm Hg) 
 
 
 
 
>80 
 
 
>95 
 
Normal 
 
<42 
 
 
 
 
50-80 
 
 
91-95 
 
>60 
 
<42 
 
 
 
<50 or response 
to therapy lasts 
<2 hours 
<91 
 
<60 
 
≥42 
 
 
 
 
<50 
 
 
<91 
 
<60 
 
≥42 
 
* Adapted from National Asthma Education and Prevention Program. Expert Panel Report 2: 
Guidelines for the Diagnosis and Management of Asthma.  National Institutes of Health Pub. 
No. 97-4051, Bethesda, MD, 1997 
 
Measurement of lung function 33,34,35 
 Measurement of lung function, particularly the reversibility of lung 
function abnormalities provide a direct assessment of airflow limitation.  
Measuring the variability in lung function provides an indirect assessment of 
airway hyperresponsiveness.   
 There are wide range of different methods to assess the level of airflow 
limitation exists, but two methods have found widespread acceptance for use 
in patients over 5 years of age, are the measurement of forced expiratory 
volume in 1 second (FEV1) and its accompanying forced vital capacity (FVC), 
and the measurement of Peak Expiratory Flow (PEF).  Both of these 
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measurements depend on the concept of airflow limitation relating directly to 
the luminal size of the airways (airway caliber) and the elastic properties of 
the surrounding lung tissue (alveoli). 
Treatment aspects of Bronchial asthma 36 
 The Expert panel of the NAEPP (National Asthma Education and 
Prevention Program) of the National Heart, Lung and Blood institute has 
developed asthma classification schemes which are useful in directing asthma 
therapy and identifying patients at high risk of developing life-threatening 
asthma attacks.  
Approach of Long-term Treatment 37 
 Current approaches are based on both the severity of the patient’s base 
line asthma and the severity of asthma exacerbation. NAEPP recommends a 
stepwise approach to therapy provided below in Table 3. 
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TABLE 3: STEPWISE APPROACH FOR MANAGING ASTHMA* 
 
 Long-Term 
Control 
Quick Relief Education 
Step 1: 
Mild 
Intermittent 
No daily medication 
needed. 
Short-acting 
bronchodilator; inhaled 
β2 agonists as needed 
for symptoms. 
Intensity of treatment will 
depend on severity of 
exacerbation. 
Use of short-acting 
inhaled β2 agonists > 2 
times a week may 
indicate the need for 
long-term control 
therapy. 
Teach basic facts 
about asthma.   
Teach 
inhaler/inhalation 
chamber 
technique.  
Discuss roles of 
medications.   
Develop self-
management & 
action plans.   
Discuss 
appropriate 
environmental 
control measures. 
 
* Modified  from National Asthma Education and Prevention Program. Expert Panel 
Report 2: Guidelines for the Diagnosis and Management of Asthma.  National 
Institutes of Health Pub. No. 97-4051, Bethesda, MD, 1997 
 
However, the inhaled forms not available for the study we are taking 
tablet form of short-acting bronchodilator.  The present study was proposed to 
conduct in mild cases. 
 
Pharmacological Agents for asthma 38,39 
 
 Asthma medications can be divided into long-term and quick-relief 
medications.  Long-term control medications (controller, maintenance or 
preventive medications) are taken daily to achieve and maintain control of 
persistent asthma by action primarily to attenuate inflammation. 
 24
 Quick relief medications are taken to promote prompt reversal of acute 
airflow obstruction and relief of accompanying symptoms by direct relaxation 
of bronchial smooth muscles. 
A. Long – Term control Medications 
In this group the agents mainly used are 
1. Anti inflammatory agent 
      Corticosteroids   -   Inhaled corticosteroids,  
    Systemic corticosteroids 
           
2. Long – acting bronchodilators 
a. Mediator inhibitors – cromolyn sodium and nedocromil. 
b. Beta-adrenergic agents – long acting β2 agonist provide 
bronchodilation for up to 12 hours after a single dose.   
Salmeterol and formoterol are the two agents commonly 
used to control nocturanal and exercise induced asthma. 
c. Phosphodiestrase inhibitors 40 
Theophylline – It provides mild bronchodilatation in 
asthmatics and may also have antiinflammatory properties, 
enhance mucociliary clearance, and strengthen 
diaphragmatic contractility.  Theophylline serum 
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concentrations need to be monitored closely owing to the 
drug’s narrow toxic  therapeutic range. 
3. Leukotriene modifiers 41 
This is the newest class of medications for long-term control 
of asthma. Leukotrienes are potent biochemical mediators 
that contribute to airway obstruction and asthma symptoms. 
Zileuton is a 5-lipoxygenase inhibitor that decreases 
leukotriene production.  Montelukast are cysteinyl 
leuktotinase receptor antagonists. 
These agents product modest improvements in lung 
function and reductions in asthma symptoms and lessen the 
need for beta-agonist rescue therapy.  These agents may be 
considered as alternatives to low dose inhaled corticosteroids 
in patients with mild persistent asthma. 
4. Desensitization 
Immunotherapy for specific allergens may be considered in 
selected asthma patients who have exacerbations of asthma 
symptoms when exposed to allergens to which they are 
sensitive and who do not respond to environmental control 
measures or other forms of conventional therapy.  
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5. Miscellaneous agents 
Oral sustained – release β2 agonists are reserved for patients 
with both some nocturnal asthma symptoms or moderate to 
severe persistent asthma who do not respond to other 
therapies. 
Corticosteroid – sparing antiinflammatory agents such as 
methotrexate, cyclosporine, intravenous immuno globulin 
and gold should be used only in selected severe asthmatics. 
B. Quick- relief Medications 42 
Short acting bronchodilators and systemic corticosteroids 
comprise the important medications in this group of agents. 
1. Beta – adrenagic agents 43  
Short acting inhaled beta adrenergic agonists are clearly the 
most effective bronchodilators during exacerbations. Beta – 
adrenergic agonists should be used in all patients to treat acute 
symptoms.  These agents relax airway smooth muscle and cause 
a prompt increase in airflow and reduction of symptoms.  There 
is no convincing evidence to support the use of one agent over 
another.  However, β2-selective agents produce less cardiac 
stimulation than those with mixed β1 and β2 activities.  
Currently available short acting β2-selective adrenergic agonists 
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include Salbutamol (albuterol), bitolterol, pirbuterol and 
terbutaline. Inhaled beta-adrenergic agonist therapy is as 
effective as oral or parenteral therapy in releaxing airway 
smooth muscle and improving acute asthma and offers the 
advantage of rapid onset of action (<5 minutes) with fever 
systemic side effects. Intravenous and subcutaneous routes of 
administration should be reserved for patients who because of 
age or mechanical factors are unable to inhale medications. 
2. Anticholinergics 44 
Anticholinergic agents reverse vaguly mediated bronchospasm 
but not allergen or exercise  - induced bronchospasm .  They 
may decrease mucous gland hypersecretion seen in asthma. 
Ipratropium bromide, a quaternary derivative of atropine free 
from atropine side effects, is the only available agent.  This drug 
reverses acute bronchospasm and is the inhaled alternative for 
patients with intolerance to β2 agonists.  It is the drug of choice 
for bronchospasm due to beta – blocker medications. 
3. Glucocorticoids 45 
Systemic Corticosteroids are effective primary treatment for 
patients with moderate to severe exacerbations (or) for patients 
who fail to respond promptly and completely to inhaled β2 
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agonist therapy.  They are one of the main stays of the treatment 
of patients with severe asthma.  These medications speed the 
resolution of air flow obstruction and reduce the rate of relapse.   
4. Antimicrobials 22,23 
Antibiotics have no role in routine asthma exacerbations. They 
may be useful if bacterial respiratory tract infections are thought 
to contribute. Thus, patients with fever and purulent sputum and 
evidence of pneumonia or bacterial sinusitis are reasonable 
candidates. 
COMPLICATIONS 41  
 The Complication of asthma include  
 Exhaustion 
 Dehydration 
 Airway infection 
 Cor pulmonale 
 Tussive and 
 Syncope 
 Pneumothroax – but is rare 
 Acute hypercapnic and hypoxic respiratory failure in 
severe disease 
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COMPLEMENTARY ALTERNATIVE MEDICINES 46 
For the purpose of Review the complementary alternative medicine 
used for the treatment of asthma is provided below. 
 Home remedies  - Natural treatment for asthma 
a. Honey (Shahad) 
b. Garlic (Lahsoon) 
c. Turmeric (Haldi) 
d. Bitter guard (Karela) root 
e. Figs (Anjeer) dry 
f. Indian gooseberry (Amla) 
g. Linseed (Alsi) 
h. Mustard (Rye) oil 
i. Dietary considerations 
j. Other measure 
1. Take enema to clear colon to prevent autotoxication. 
2. Application of mud-pack to the abdomen. 
3. Wet chest packs and steam bath. 
4. Breathing exercises, dry climate 
5. Mild physical exercises and correct posture 
 
k. Management of Bronchial asthma with Herbomineral, Ayurvedic 
Drugs. 
 30
l. Salt therapy for Asthma 47 
 It is not a new concept – inhaling the salt air steam from heating 
salt solution was recommended treatment from the days of  
Hippocrates. 
m. Spleotherapy48 or Underground climatotherapy is an alternative 
treatment for asthma used mostly in Eastern Europe.   
 
PREVENTIVE ASPECT 23,38  
 
Patient Education 
 
 Patient education is a necessary component to successful 
management of both acute and chronic asthma.  It  
- need to realize the repetitive and progressive nature of their asthma 
and  
- educate them to live safely and as symptom – free as possible and  
- Motivated to learn the pathophysiology of asthma, factors triggers 
(e.g) Avoid contact with allergens, Avoid aspirin NSAID agents 
when possible. 
- Oriented towards Medication actions and side effects. 
-  Motivated to monitor there airway function objectively by 
expiratory peak flow measurements 
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- thoroughly familiarized themselves with the proper use of inhaled 
bronchodilators and spaces. 
- Patients and their physicians need to recognize, and allow them to 
the emotional impact of asthma on their lives and families.   
Only through open, unrushed and empathic communication can the 
physician open the door to this important interaction. 
Vaccination 
Patients with persistent asthma should receive the Pneumococal 
vaccine (Pneumovax) and annual influenza vaccinations. 
Dietary considerations as followed in complementary alternative 
medicines 
 In dietary considerations the patients should avoid the common dietic 
errors. Ideally, diet should contain limited acid forming foods like 
carbohydrates, fats and proteins and a liberal quantity of fresh fruits, green 
vegetables and germinated gram.  Foods tend to produce phlegm such as rice, 
sugar, lentils and curds as well as fried and other difficult to digest foods 
should be avoided.  Asthmatics should always eat less than their capacity. 
 
Do’s and Don’t in Bronchial asthma in Ayurveda 16 
 * Do not have chilled cold drinks, ice creams etc., 
 * Do not have fish / fish products  
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 * Do  not have excessive oily and spicy pungent food 
 * Do not sleep at very Late night 
 * Do not have tension or stress 
 * Do not have any self medicine 
 * Take medications regularly without any gap 
Research area in bronchial asthma 4,6 
A few reports document the usefulness of these medications. The 
research areas are:  
1.  Effect of erythromycin as a mucolytic agent 
2.  Effect of furosemide by altering the sodiumchloride membrane                             
     transport system  
3. Atrial natriuretic factor 
4.  Glucagon effects under trial 
5 . Omalizumab –first biological drug approved for bronchial asthma a     
       recombinant human monoclonal antibody targetting IgE antibodies  
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MATERIALS AND METHODS 
 
SETTING  
 The present study was carried out in the outpatient department of 
thoracic medicine, Government Rajaji Hospital, Madurai.  
 
COLLABORATING DEPARTMENTS  
This study was carried out in collaboration with  
- Institute of Pharmacology,  
- Department of Thoracic Medicine, and  
- Department of Biochemistry  
 
DESIGN OF STUDY  
 It was a open label, single centre, randomized comparative trial.  
 
STUDY DURATION [August 2004 – March 2006] 
1. Literature collection – 3 months  
2. Designing the study – 1 month  
3. Case selection and drug administration – 12 months  
4. Analysis and follow up – 2 months  
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5. Interpretation – 1 month  
6. Discussion – 2 months   
SAMPLE SIZE  
 Total sample was 50 (25+25) cases, those who satisfied a rigid 
inclusion and exclusion criteria.  
ETHICAL APPROVAL  
 Institutional ethical clearance was obtained from the ethical committee, 
Government Rajaji Hospital, Madurai [Annexure I]. Letter No: 1419/E4/3/04/ 
O/o. Dean, GRH, Madurai dated 27-01-2005 
INFORMED CONSENT  
 Informed consent was obtained from all the patients. They were 
personally explained, dated and signed in duplicate by both patient and the 
investigator [Annexure II]. 
SELECTION OF STUDY SUBJECTS (i.e. cases) 
       Patients of both sexes suffering from mild asthma [as per GINA table-2)  
attending thoracic medicine outpatient department selected by the professor 
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Department of Thoracic Medicine, Government Rajaji Hospital, Madurai. By 
using peak expiratory flow meter (PFM), the PEFR was recorded. They were 
started on salbutamol inhaler (100mg/puff) 2 puffs at 10 minutes interval and 
the difference in the improvement before and after inhalation was recorded by 
using PFM. Those who showed improvement in PEFR more than 15% or 
>200ml were selected for study.  
INCLUSION CRITERIA FOR THE PRESENT STUDY ARE:   
* subjects with asthma (GINA-mild) 
 Patients who were grouped / classified under mild asthma as per GINA 
were considered for the study because of the following reasons.  
1. They can be managed with single molecule.  
2. Easy to convince for the study.  
3. Unlikely to develop disease related complications, emergencies.  
* Age group (25-40 years) 
    Patients within 25-40 yrs of age group were selected because  
• They can be made to understand easily  
• They will cooperate better for follow up  
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• Of economical independence.   
* Subjects with PEFR - performance 
Only those patients who showed an improvement of 15% after                                           
inhalational bronchodilator therapy were included.  
* Subjects willing for the study  
 Subjects were explained about the proposed study, the need for follow 
up and the necessity to follow a healthy life style. Only those subjects who 
accepted to adhere to this guideline were considered for the study.  
* BMI ranges from 19-23  
 Those patient’s whose BMI was within 19 to 23 were considered so as 
to have homogeneity as well as to have  uniform pharmacokinetic parameter, 
and they are unlikely to have abnormal lung function.  
* Literacy state 
 At least patients with ability to read and write Tamil were included in 
order to follow home care instructions carefully. 
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EXCLUSION CRITERIA  
 The patient who had any one of the following (or) a combination of 
them was excluded.  
* Age 25 - 40   
 Subjects of less than 25 yrs may be less cooperative and those above 40 
yrs might be suffering from the disease for longer duration (or) may be hailing 
disease related complications, co-morbid conditions.  
* Unwilling / non-compliance  
 Those not willing to participate (or) who did not have the intention the 
consent for compliance were excluded.  
Personal habits 
* Tobacco users – smoking, alcohol, drug addiction 
 Smokers both active and passive, Alcohol consumers and drug addicts 
(e.g. Cannabis indica) were excluded.  
* Those practicing yoga, pranyama (or) breathing exercise  
    As their yogic exercise will influence the air flow, those practicing such 
were excluded.     
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* Physiological status   
           Special restrictions for female patients  
 The hemodynamic changes and hormonal variations during the 
physiological status – pregnancy, women in periods & nursing female patients 
were excluded.  
* Hematological aspects  
            As Anemia (or) other hematological disorder contribute to 
breathlessness, those cases were excluded.  
* Respiratory system  
              Severe bronchial asthma, COPD, respiratory infection, eosinophilia 
pulmonary tuberculosis (old & active) pulmonary hypertension, thoracic 
abnormalities, and patients undergone previous lung volume reduction surgery 
were excluded. 
* Cardiovascular system  
              Those with hypertension, cardiac disease or pericardial disease were 
excluded.     
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* Endocrine and metabolic system  
              Those with diabetes mellitus, hypothyroidism, obesity were excluded.  
* GIT  
         Gastroesophageal reflux disorder (GERD), ascitis, liver disease, because 
GERD can induce asthma by triggering airway narrowing in susceptible 
persons.  
* Renal system  
           Those with acute (or) chronic renal problems were excluded.  
* Immune system  
             Those on steroids, HIV/AIDS, renal transplantation.  
*Central nervous system  
              Those with neuro-psychiatric illness, unconscious, and nonambulant 
were excluded.  
* Connective tissue disorders  
              Collagen disease and Autoimmune disease were excluded. 
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* Concomitant medication  
              Those patients consuming complementary and alternative medicines 
internally or consuming analgesic agents were excluded.  
* Previous participation  
          Those who participated in similar drug trial elsewhere were excluded.  
* Others 
 Patient subjected to thorough systemic examination were excluded if 
any one of the systemic abnormalities were identified. 
* DISCONTINUATION CRITERIA  
 Patients were permitted to discontinue from the study, once they were 
decided to do so. Patient when found to develop other illness (or) worsening 
of the existing illness (or) requiring additional drugs, they were withdrawn 
from the study.  
CASE SELECTION  
 Thus, 50 cases were selected over a period of 6 months. Counselling 
was given to them on the proposed study for this purpose. Patients were 
informed verbally and in writing by the investigator about the nature, 
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significance, implications and risks of the study prior to enrollment. All items 
were explained by the investigator in a language and in terms that were easy to 
understand by the patient. Informed consent was obtained for all patients 
personally dated and signed by both the patient and investigator. The details of 
the investigator (name, phone number, and contact address) were given to 
each and every patient, to enable them to contact for any ailments at anytime 
during the study period.  
CONDUCT OF THE STUDY  
Visit 0 (V0)  
 Patient information sheet and informed consent procedure as well as 
inclusion and exclusion criteria were considered   
Data collection  
 Following data were collected. 
Socio-demographic data   
 In this, name, age, sex, address, education qualification, occupation, 
living environment, working place environment, travelling time to reach 
hospital were collected.  
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Medical History  
- H/o present illness  
- H/o previous drug intake  
- H/o associated allergic disorder  
- Allergic rhinitis  
- Eczema  
- Atopy 
- H/o occupational exposure to  
 Smoke   
 Chemical  
- Family History  
• H/o similar illness in their family  
- Personal history  
• Smoking  
• Veg / Non-veg  
* Physical examination  
 Height / Weight / BMI  
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* Laboratory Investigation  
 Blood samples were collected from each patient for determination of 
the following parameters.  
 Complete blood count  
 Biochemical investigation 
 Haemoglobin  
 Blood sugar, urea  
 Serum creatinine  
 Serum potassium  
 Renal function test  
 Urine analysis  
* Micro biological investigation  
 Sputum examination for gram stain and AFB stain were done.  
* Image science  
1. X-ray chest PA view after deep inspiration  – to rule out any other 
lung abnormalities  
2. ECG was taken to assess cardiac status . 
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TABLE 4:  STUDY MEDICATION, DOSAGE AND STORAGE 
Details of the drugs Racemic salbutamol  Levosalbutamol  
Brand Name 
Batch no.  
Asthalin (Cipla) 
 4mg M.LDD/L/235 
 B.No. DJ 5118 
Levolin (cipla)  
2mg M.L.616 
B.No. X40160 
Manufacturing date & .  
Expiry date 
4mg – mfd – May 04 
 Exp Apr - 08 
 
Oct – 2004 } 
Sep – 2006 } for 2mg 
Drug formulation & 
Strength & package  
Tablet  
4mg/ blister pack 
Tablet  
 2mg / blister pack  
Route of administration  Oral  Oral  
Dosage Regimen and 
intake  
3 times a day after food 2 times a day after food 
Cost 4mg/Rs.5.14 per 10 tablets 2mg/Rs.8 per 10 tablets 
 
Labelling of study medication   
 The stripes of tablets were cut into single units and the required number 
of tablets for 15 days were placed in a cover were given to the patient on visit 
0 and they were asked to bring empty blister packs for pill counting. They did 
not have any concomitant chest diseases. They were assuring not to take any 
supportive or concomitant medication. While they were on these drugs, they 
were advised not to take any other medications without the knowledge of 
investigator.  
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Start of Treatment and Instruction of Patients 
 Treatment started on the day of visit 0. The date of first administration 
of the study medication was documented in the corresponding schedule of 
visists. Instructions were given to the patient to adhere to those instructions 
Each patient was advised to return the used blister packs at visit 1 in order to 
maintain accountability of study medication. 
Adverse effects: 
 Patient were given a card carrying details of adverse effects in 
Vernacular language as shown below and motivated them to mark the side 
effects / experienced during drug therapy on a meticulous manner.  These 
cards were analysed during review visit of the patient. 
∗ Overdose  
   Clinical sign of intoxications were explained instructions were given to 
avoid overdose. 
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∗ Patient Assessment  
 With reference to the aim the patients were assessed for pulmonary 
function by simple instrument peak flow meter before and after drug 
administration at weekly intervals, the details were recorded.  
* Pulmonary function assessment  
• Instrument used – peak flow meter  
• Frequency – before and after drug at weekly intervals  
* Clinical Assessment  
 Pulse rate, respiratory rate, blood pressure and side effects were 
evaluated.  
   * Biochemical assessment  
•  Blood collection for serum potassium level before and after drug 
administration was done following standard precautions.  
Financial Support 
 The funds required for the purchase of drugs were made available by 
the funds contributed by the Department of thoracic medicine and 
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pharmacology.  Patients follow up and incentives provided by the above 
funds.  
Study monitoring, auditing and inspections  
 In order to ensure adherence to the guidelines, audit and inspections 
were done by thoracic department and pharmacology department.  
Outcome of the study  
 Outcome of the study was assessed by clinical improvement, symptom 
assessment, bio chemical investigations and pulmonary function tests. 
Statistical Analysis  
 The effect of drug therapy is analysed by paired ‘t’ test.  Patients age, 
gender, pulmonary function and adverse effects were subjected to statistical 
analysis. 
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RESULTS 
 
In this study there were 11 males and 14 females in racemic salbutamol 
group,  and 10 males and 15 females in levosalbutamol group.  The age ranged 
from 25 to 40 in racemic salbutamol group, and 23 to 39 years in 
levosalbutamol group.  The BMI of both groups varied from 19 to 23 and the 
mean was 21.  Economicial status in both the category  ranged from 600 to 
900 rupees/month.  The clinical data, ECG, X-ray chest and Haematology  
were nil contributory.  However, they had episodes of wheezing over a period 
of 5 years. The details are provided in table 5.  
 
TABLE 5: CHARACTERISTICS OF STUDY POPULATION 
 
Basic Characteristics Racemic Salbutamol Levosalbutamol  
Gender 
      Male 
      Female 
 
Age in years 
      Range 
       Median 
        ±SD 
 
11 
14 
 
 
25-40 
31 
4.69 
 
10 
15 
 
 
23-39 
30 
4.31 
 49
 
BMI 
Mean 
Economical status 
Range in Rupees. 
 
Clinical data 
ECG 
X-ray Chest 
Hematology 
        
 
19 – 23 
21 
 
600 – 900 
 
 
Nil Contributory 
Nil Contributory 
Nil Contributory 
 
19-23 
21 
 
600 – 900 
 
 
Nil Contributory 
Nil Contributory 
Nil Contributory 
    
        Distribution of cases in relation to age and gender are shown in Table 6 
for racemic salbutamol and levosalbutamol given below 
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TABLE 6: DISTRIBUTION OF CASES IN RELATION TO AGE AND 
GENDER 
 
Levosalbutamol Racemic Salbutamol Age in 
years Male Female Total Male Female Total 
25-39 3 6 9 3 5 8 
30-34 4 5 9 5 5 10 
35-40 4 4 7 3 4 7 
Mean 32.59 32.23 32.32 32.5 32.41 32.4 
SD 0.79 0.86 1.19 0.74 0.89 1.16 
Median  28.12 26.0 29.5 27.5 27.0 27.25 
 
Not significant in relation to age between these groups 
 
 
The past history of allergic disorder 35 in the form of nasal stuffiness, 
sneezing, itching over the skin, utricarial rashes were noticed in 3 among 25 in 
racemicsalbutamol group and 5 among levosalbutamol group.  Family history 
of similar allergic illness was found in 2 and 1 among racemic salbutamol and 
levosalbutamol groups respectively.  Renal function test and liver function test 
did not reveal any abnormalities. 
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TABLE 7:  DISTRIBUTION OF CASES IN RELATION TO 
ALLERGIC DISORDER AND FAMILY HISTORY 
 
Sl.No. Clinical / Lab Racemic 
Salbutamol 
(n=25) 
% Levo 
Salbutamol 
(n=25) 
% 
1 H/o. patients associated 
with allergic disorders 
3 12 5 20 
2 Family H/o. similar 
illness 
2 8 1 4 
3 Renal function test* Within normal 
limits 
 Within normal 
limits 
 
4 Liver function test ** Within normal 
limits 
 Within normal 
limits 
 
 
* serum creatinine  ** serum enzymes bilirubin, albumin, globulin 
 
 
Pulmonary function with PEFR before and after oral administration of 
Racemic Salutamol and levo salbutamol are provided in Table 8. 
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TABLE 8: PEAK EXPIRATORY FLOW RATE COMPARISON 
AMONG TWO MOLECULES OF SALBUTAMOL 
 
Racemic Salbutamol Levo Salbutamol  
PEFR Mean ± SD Median Mean ± SD Median 
Before 249.6  / 66.36 220.0 254.8 / 50.59 175.29 
After 265.2 / 64.10* 250.0 309.6 / 55.94** 202.94 
 
                      *Significant P = 0.0047                                      **p = 0.0000175 
 
 
The patients were grouped into those receiving racemic salbutamol as 
group I and those receiving Levosalbutamol as group II.  The mean PEFR 
before and after therapy in group I was 249.6 and 265.2 respectively and the 
mean in group II was 254.8 and 309.6 respectively. The  pulmonary function 
improved significantly (table 8) after oral exposure to salbutamol irrespective 
of the type.  However the improvement was very high in the levosalbutamol 
group (p=0.0000175) thus indicating the levosalbutamol has better effect as 
bronchodilator. Of the biochemical test, serum potassium level among the 
study groups both before and after revealed some changes.  The serum 
potassium level among these cases before and after salbutamol was provided 
in table 9.  In both the categories potassium level at the end of  2 weeks was 
slightly more than what it was in the beginning.  The details are provided  in    
table  9. 
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TABLE 9:      SERUM POTASSIUM LEVEL  
             BETWEEN THE STUDY GROUPS 
 
Sl. 
No. 
Groups Potassium  
Level 
Before After Significance 
1 Racemic 
Salbutamol  
 
Mean ± SD 
Median 
Mode 
4.1 ± 0.4397 
4 
4 
4.204 ± 0.6024 
4 
4 
Not 
significant 
2 Levo 
Salbutamol 
Mean ± SD 
Median 
Mode 
4.208 ± 0.4349 
4.2 
4 
4.28 ± 0.5156 
4.24 
4 
Not 
significant 
The nature of side effects observed in both the groups were provided in 
table 10.  Tachycardia, tremor and muscle cramps were significantly low in 
levosabutamol group. 
TABLE 10: NATURE OF SIDE EFFECTS 
 
Sl.
No 
Side Effects Racemic Salbutamol 
(n=25) 
% Levo Salbutamol 
(n=25) 
% Significance 
1 Palpitation  10 40 2 8 0.0063 
2 Muscle Cramps 10 40 3 12 0.0213 
3 Tremor 17 68 3 12 0.00001 
4 GERD 3 12 0 0 - 
5 Polyurea 2 8 0 0 - 
 
Side effects Significantly less with levo salbutamol 
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DISCUSSION 
 
 
Bronchial asthma is a disease known for centuries and description is 
made in different systems of Medicine. Despite enormous advances in the 
management of asthma, till we do not have any definitive drugs.  However, 
salbutamol is one of the commonly used bronchodilator in day to day practice.  
Systematic name of Salbutamol is (±) alpha 1-[(tert-
butylamino)methyl]-4-hydroxy-m-xylene-alpha, alpha’-diol. The generic class 
of the drug is beta2-adrenergic bronchodialator.  It is included under FDA 
drug as Antiasthmatics / Bronchodilators. The molecular formula of 
Salbutamol is C13H21NO3 and the molecular weight is 239.31g/mol.  The 
melting point is 157-1580C (with decomposition). Salbutamol is a white or 
almost white, crystalline powder when dissolved in methanol the solution is 
clear and very pale yellow in colour. Solubility of Salbutamol is sparingly 
soluble in water;  but soluble in ethanol (96%); and slightly soluble in ether 
also. 49  
It has C, H, N & O molecules and the percentage of the same was  
65.25%,8.84%,5.85%, 20.06% respectively and it is marketed in almost all 
countries under different brand names.  It is available as single molecule or in 
combination. In India Salbutamol marked as either in single molecule or in 
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combinations with various drugs like Corticosteroids in various drug 
formulations. Some of them were mentioned below:  
Salbutamol available in India in various drug formulations and 
marketed by different companies in simple or as sustained release or 
controlled release form etc.,   
Tablet form: E.g., Asthalin, Salbetol, Salmaplon, Bronkotab. 
Syrup form: E.g., Salbu, Asthalin, Ventrolin 
Capsule: E.g., Salbair Trans-Cap 
Rotacap: E.g., Asthalin 
AC-Inhaler/MDI: E.g., Asthalin 
Combination Formulations: 
Rotocap/MDI : E.g., Aerocart (Salbutamol 200mcg+ Beclomethasone  
                           dipropioate 100mcg)  
HFA Inhaler: E.g., Asthalin 
Duolin Inhaler/MDI: E.g., Ipratropium Bromide 20mcg,  
     Salbutamol 100mcg  
Bronchilet: E.g., Salbutamol, Hydroxy ethyl Theophylline 124mg 
 
The market price of salbutamol as a lone molecule vary from 10 paise 
to 35 paise for a strength of 2mg, 16 paise to 52 paise for 4mg tablet and for 
90 paise to Rs.1.25 paise for 8mg. 
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Salbutamol was developed from the modification of Norepinephrine, a 
natural neurotransmitter. Norepinephrine stimulates α and β adrenoceptors in 
the body, a more specific drug was need that targetted only the β 
adrenoceptors. It was found that the replacement of one hydrogens on the 
amine with a isopropyl group produced isoproterenol (isoprenaline) which has 
increased stimulation of β adrenoceptors whilst a reduce stimulation of   α 
adrenoceptors.  However Isoproterenol was not metabolically stable and was 
inactivated by the enzyme catechol O-methyltransferase too quickly to be 
usefully used in the treatment of asthma. Another disadvantage was the there 
are two types of β adrenoceptors, β1 and β2, isoproterenol activated both 
receptors The activation of β1 adrenoceptros in the cardiovascular system gave 
rise to side effects such as palpitations and cardiac arrhythmia. 50,51 
  This widespread, regular use of beta2 agonist drugs as a class, 
particularly in the absence of inhaled corticosteroids, could potentially lead to 
worsening asthma control.  This may be due to rebound airway 
hyperresponsiveness;  as a result the patient might require higher doses, 
resulting in incidence of beta-mediated side-effects like tachycardia, tremors, 
hypokalaemia etc.,52 All this has led to relook at the available beta2-agonists to 
develop more safer and therapeutically active agents.  Synthetic β2-agonist 
bronchodilators are developed based upon the structure of epinephrine and are 
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thus supposed to mimic the bronchodilating action of epinephrine. However, 
endogenous epinephrine is a pure single  isomer  (R) – epinephrine, whereas 
most of the β2 – agonists including salbutamol are racemates.  Salbutamol is 
racemic compound composed of a 50:50 mixture of two non superimposable 
mirror image isomers. 
Although Salbutamol was first synthesized in 1969 there is still much 
research into better, quicker and more efficient syntheses of R-Salbutamol.  
There is currently only one major synthesis of R-Salbutamol although there 
are many possible ways of producing pure samples of R-Salbutamol via 
distereomeric resolution. 
 In the present study the clinical improvement in the form of improved 
PEFR was noticed after exposure to oral levosalbutamol which was highly 
significant (P=0.0000175) in contrast to racemic salbutamol.  Since inhaled 
form of levosalbutamol was used in many studies in different countries, it was 
taken into consideration for comparative analysis with present work.  In the 
present study the variability in serum potassium level was noticed after 
administration of drug by different authors and the comparative analysis is 
shown in the table 11 below. 
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TABLE 11. COMPARATIVE ANALYSIS WITH REFERENCE TO  
PULMONARY FUNCTION 
 
Sl.
No. 
Author, Year, 
Country, 
Number 
of cases, Study 
type 
Outcomes Key results Study 
weaknesses 
1 Lipworth Bjet 
al, 1997, UK 
n=12 
PCRT  
Tremor, plasma 
potassium, heart 
rates were 
measured 
Potassium 
values  
(p  values not 
provided) 
Small sample 
size.  
2 Gumbhir Shah 
K et al, 1999, 
USA 
n=13 
RCT  
FEV1 plasma, 
potassium, heart 
rate 
 
No change in 
plasma 
potassium levels  
 
 
Small sample 
size  
3 Lotvall J etal, 
2001, Sweden 
n=20 
PCRT 
FEV1 heart rate 
and plasma 
potassium levels.  
 
Side effects  
Rapid increase 
in plasma 
potassium level  
No serious 
adverse events  
Small sample 
size. 
4 Pancu D et al, 
2003, USA 
n=27 
RDBPCT  
Serum 
potassium values 
at baseline 
 
 
 
Side effects 
No difference 
between any 
group. No side 
effects. 
Levosalbutamol 
caused fewer  
side effects  
Potassium is 
uncertain and 
these changes 
may not be 
applicable.  
5 Present Study 
2004, Madurai 
n=25 
RSBCT 
 
PEFR, serum 
potassium 
values, heart rate 
 
Side effects: 
muscle cramps, 
palpitation, 
tremor, GERD, 
poly urea 
Significant 
improvement in 
Levo salbutamol 
group. 
Side effects  
less in 
levosalbutamol. 
PCRT  - Placebo control randamised trial  
RDBPCT  - Randamised double blind placebo control trial  
RSBCT - Randamised single blind control trial  
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 The reasons for variable levels in serum potassium among different 
population could be due to dietary variation, renal clearance of potassium and 
pharmaco kinetics of levosalbutamol as well as genetic contribution for 
potassium level in the body.  In addition initial serum potassium level might 
have also contributed.  Moreover, the serum potassium level was carried out at 
two different occasions and this might also have contributed. 53,54  
 Several studies have suggested an association between Beta agonist use 
and an increased risk of death from asthma.  Proposed mechanisms include 
increased bronchial hyperresponsiveness, drug tolerance or an underlying 
increased severity of disease.  Such analyses support the continued use of 
salbutamol  as a first line therapy for the treatment of asthma.    
 This apparent controversy appears to be due to the two different 
isomers have opposing effects.  R-Salbutamol causes smooth muscle to relax 
whereas S-salbutamol causes smooth muscle to contract.  The two isomers act 
on different receptors and thus on different pathways resulting in the opposing 
effects.  
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 S-salbutamol is now thought to be the main cause of bronchial hyper 
responsiveness in the treatment of asthma with salbutamol.  S-salbutamol acts 
on muscarinic receptors.  There are also G linked proteins and also have seven 
trans membrane domains. Being a G linked protein the conformational 
changes and the dissociation of the alpha sub unit is identical to that of the 
beta two receptor.  However the alpha sub unit activates a different enzyme in 
this pathway.  In this pathway the alpha sub unit activates phospholipase C. 
This enzyme catalyses the phosphorylation of Phosphatidylinositol 4,5-
bisphosphate (PIP2) to inositol 1,4,5-triphosphate (IP3) on the inside of the 
membrane.  This small molecule (IP3) is no longer bound to the membrane 
and leaves the plasma membrane and diffuses through the cytosol.  In the 
cytosol it releases Ca2+ from the endoplasmic reticulum (ER) by binding to IP3 
gated Ca2+ release channels in the ER membrane or ryanodine receptors in the 
sarcoplasmic reticulum of muscle cells.  This initiates a positive feedback 
system as the Ca2+ released can bind back to the channels releasing more Ca2+ .  
Thus S-salbutamol initiates a sudden increase of Ca2+ ions which initiates 
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muscle contraction, which contributed to more side effects / adverse 
reactions.55  
 In view of the opposing effect, research were made to isolate R-
Salbutamol from the racemic mixture.  The mechanism of muscle relaxation 
due to R-Salbutamol furnished below. R-Salbutamol acts on Beta 2 
Adrenergic Receptors.  These receptors are found on the smooth muscle lining 
airways of the lungs.  The binding of R-salbutamol to this receptor causes a 
conformational change in the protein.  β2 adrenergic receptors are an example 
of a G linked protein, the receptor has seven trans membrane domains and is 
associated in the membrane with a G protein.  The G protein has three sub 
units ( an alpha sub unit tightly associated beta and gamma sub units).  The 
conformational change in the β2 receptor causes in the G protein. A guanosine 
5’-diphosphate (GDP) group associated with the G protein becomes 
dissociated and is then replaced with  guanosine 5’-triphosphate(GTP) group.  
This is turn causes the alpha sub unit to dissociate from the G complex.  The 
dissociated alpha sub unit is then free to move in the membrane and has a 
binding site for the enzyme adenylyl cyclase.  It binds to an adenylyl cyclase 
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and activates it.  This enzyme catalyses the conversion of ATP to cAMP 
(adenosine5;-triphospahte to adenosine 3’,5’-monophosphate).  cAMP levels 
in the cell therefore increase due to the additional adenylyl cyclase produced 
by the binding of R-salbutamol. cAMP activates protein kinase A (a cyclic 
AMP dependent protein kinase).  Protein kinase A transfers the terminal 
phosphate group of an ATP to several target proteins within the cell which 
leads to muscle relaxation. 49  
Mechanism of Action of β2 agonists is described in pictorial manner 
below 
 
   β2 agonists                β2 receptor 
 
 
        Adenylyl  Cyclase 
     
ATP                         3’,5’ –cAMP 
 
Decreases intracellular Ca2+ 
      
 
Smooth muscle cell relaxation 
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The phosphorylation process leads to muscle relaxation by several 
processes including active removal of Ca2+ ions from the cell and into 
intracellular stores, thus lowering intracellular Ca2+ ion concentration. Ca2+ led 
to inhibition of  Phosphoinositid hydrolysis which inturn led to direct  
inhibition of myosin light chain kinase activity, thus opening of calcium 
activated potassium channels that repolarises smooth muscle cells.  Muscle 
concentration is initiated by a sudden rise in cytosolic Ca2+ ions concentration 
and reduced cytosolic Ca2+ concentration will cause muscle relaxation. 56 
Thus R-salbutamol can cause muscle relaxation irrespective of the 
method of initiation of the muscle contraction (the contractile agent, be it 
neural or mediated).  As asthma is caused by many different contributions 
leading to muscle contraction and makes salbutamol a suitable drug for its 
treatment. 
R salbutamol also has several other beneficial effects on the lungs 
(other than smooth muscle relaxation ) and they are  
 a. Inhibition of mast cell mediator release 
 b. Increases mucous secretion and  
 c. Increased clearing of the mucus by the action of cilia. 
However R-salbutamol has no effect on chronic inflammation. Through 
the inhibition of mast cell mediator release, which is anti-inflammatory, R-
salbutamol can to an extent also modify acute inflammation an another 
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symptom of asthma.  In the present study the PEFR improved remarkably as 
observed by other authors.  This salbutamol contributes to relaxation of 
smooth muscle of bronchi and thereby improves the pulmonary function.  In 
general the component of S-Salbutamol in racemic form causes smooth 
muscle to contract.  Interestingly two isomers that is R-Salbutamol, S –
Salbutamol act on different receptors in different pathways resulting in 
opposing effects.  The mechanism of opposing effects is in contradiction to 
expectation is furnished below. 
In the present study side effects such as  muscle cramps, palpitation, 
tremor, GERD and  Polyurea were more among racemic than levo salbutamol 
group. Studies have found peak plasma concentrations occur approximately 2 
to 5 minutes after inhalation and 2 to 2.5 hours after ingestion.  Salbutamol is 
metabolized in the liver, mainly by conjugation to the inactive salbutamol-4’-
0-sulphate.  Salbutamol’s plasma half life is reportedly 2.7 to 5 hours after 
oral administration.  The half life has been indirectly estimated through urine 
excretion studies to be 3.8 hours after inhalation.  Unchanged drug and 
metabolite are 72% excreted in the urine within the first 24 hours.  R-
Salbutamol being an analog of human (R) – epinephrine is a more natural 
substrate for the sulfotransferase enzymes and therefore is more rapidly 
sulphated and eliminated than (S) – Salbutamol.  Accordingly markedly 
elevated plasma levels of (S) – Salbutamol are seen after dosing with racemic 
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salbutamol.  This is a major concern when repeated dose of racemic 
salbutamol are administered, which might lead to accumulation of (S) – 
Salbutamol and which might be responsible for worsening of the disease, 
considering the detrimental effects that have been reported with (S)-
Salbutamol.  Levosalbutamol appears to be stereochemically stable in vivo 
and does not appear to interconvert metabolically to (S) – salbutamol. 57, 58 
The difference between the action of leveosalbutamol versus racemic 
salbutamol in relation to cellular,   experimental and clinical properties are 
provided in table 12 given below: 
 
TABLE 12: CELLULAR, EXPERIMENTAL AND CLINICAL  
PROPERTIES OF (S) AND (R) SALBUTAMOL * 
 
  
Properties (S) Salbutamol (R) – Salbutamol 
Receptor 
Binding 
 
Calcium 
concentration 
 
Eosinophil 
Histamine 
 
 
Airway 
response 
 
 
 Does not bind toβ2 receptors 
 
 
 Intracellular calcium 
concentration 
 
 Eosinophil activation 
 
 Histamine-induced epithelial  
permeability 
 Always protein, neutrophils, and 
IL8  
 
 Airway tissue response to 
spasmogens  
 
 
Specifically binds to β2 receptors 
 
 
   Intracelluar calcium concentration 
 
 
   Eosinophil activation 
 
   Histamine-induced epithelial 
permeability 
  Always protein, neutrophils, and IL8  
 
 
   Airway tissue response to 
spasmogens 
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Tissue response 
 
Accumulation 
Therapeutic 
effect 
Pulmonary 
function test 
Bronchodilatory 
potency 
Difficult to metabolize; unnatural 
molecule.  
Accumulates with regular dosing 
 
Demonstrates no bronchodilatory 
effect 
 
Not inert: may be clinically 
detrimental 
 
 Overall racemic bronchodilator 
potency 
 
Easy to metabolize; natural analog 
 
Shows no evidence of accumulation 
 
Achieves all therapeutic 
bronchodilatory effect 
 
Does not diminish lung function with 
chronic use 
 
   Overall bronchodilatory potency 
 
 
 ↑ increases or enhances     ↓    reduces or inhibits 
* Source:  FDA Medical Reviewer, 1999 
  
 (S) salbutamol not only fails to relax airway smooth muscles but under 
certain circumstances may augment bronchoconstriction;  Increased 
intracellular calcium in airway smooth muscle and bronchial hyper 
responsiveness; activates phospholipase C and induces calcium influx into 
airway smooth muscle, changes that could lead to bronchial 
hyperresponsiveness.  
From the present study it is clear that oral form of levosalbutamol has 
distinct advantage for those patients suffering from bronchial asthma.  The 
observations were supported with available literature since the cellular, 
experimental and clinical properties of R – Salbutamol are superior to S- 
Salbutamol, a component of racemic salbutamol. Hence, it is suggested that 
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levosalbutamol (R-Salbutamol) may be used in day to day clinical practice for   
the patients who are in need of the same. 
The strength of the study was, a rigid inclusion criteria, close 
monitoring and supervision by specialists, and regular follow up with 
subjective and objective means.  
However, there were limitations as in any study and they were 
a. Post study follow up not done, 
b. Observer bias single blind   
c. Arterial blood gas analysis not done and spirometry not used 
due to technical constrains. 
 
d. Pharmacokinetic studies not done   
e. No cross over study done and   
f. Nebulised  form  not used                       
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CONCLUSION 
 
The following conclusions were arrived, 
a. The efficacy and tolerability of Levosalbutamol was better than 
Racemic salbutamol.  
b. Side effects were less in the Levosalbutamol group. 
c. Highly significant improvement in PEFR was noticed in those used 
Levosalbutamol. 
d. In view of the clinical and therapeutic advantage observed among 
the patients with mild bronchial asthma, oral form of 
Levosalbutamol is recommended for such cases. 
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SUMMARY 
 
 
 Bronchial Asthma is known for time immemorial.  Variety of 
therapeutic agents though available in different systems of medicine, modern 
scientific medicine try to act at the cellular level to some extent with 
constraints. 
 Among the modern pharmacological agents use for bronchial asthma, 
salbutamol is included in the WHO’s essential drug list. However, the 
available form is in racemic form with inherent side effects.  A newly 
available oral form such as levosalbutamol (R-salbutamol) is shown to have 
better than conventional one.  Hence, the present study was undertaken  
1. To compare the efficacy and tolerability of Racemic salbutamol and 
Levosalbutamol.  
2. To identify the side effects of each, and to recommend the appropriate 
one   
After the institutional ethical clearance and informed consent, a single 
blind open label randomized comparative trial was attempted among 50 (25 in 
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each group), mild bronchial asthma patients who satisfied a rigid inclusion and 
exclusion criteria.  Their socio demographic,  clinical, and laboratory data 
were collected.  They were trained, counselled  and explained about the study 
and were given respective salbutamol orally after food.  Subjective and 
Objective assessment (using PEFR) were made along with side effects. The 
data were analysed statistically. 
   There were 11 males and 14 females in racemic salbutamol group, and 
10 males and 15 females in levosalbutamol group.  The age ranged from 25 to 
40 in racemic salbutamol group, and 23 to 39 years in levosalbutamol group.  
The BMI of both groups varied from 19 to 23 and the mean was 21.  They had 
episodes of wheezing over a period of 5 years, there hematology, bio chemical 
tests, liver function test, renal function test, X-ray, ECG were nil contributory.   
The patients were grouped into those receiving racemic salbutamol as group I 
and those receiving levosalbutamol as group II.  The mean PEFR before and 
after therapy in group I was 249.6 and 265.2  respectively, and the mean in 
group II was 254.8 and 309.6 respectively.  The pulmonary function improved 
significantly (Table 8) after oral exposure to salbutamol irrespective of the 
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type.  However the improvement was very high in the levosalbutamol group 
(p=0.0000175), thus indicating the levosalbutamol has better effect as 
bronchodilator.  Side effects were negligible in levosalbutamol group.  There 
was no gross alteration in serum potassium level after therapy.   
 In view of the efficacy, tolerability and significant improvement in 
PEFR with negligible side effects observed among levosalbutamol group, it is 
recommended that oral levosalbutamol can be used for those with mild 
bronchial asthma. 
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 ANNEXURE I 
 
  
 
 ANNEXURE II 
Informed Consent Form  in English 
 
 
Full name of the patient (in capital letters): ___________________________ 
Address: _______________________________________________________ 
Date of birth: ____________ Patient Number: ___________  Sex: _________ 
I freely agree to participate in the above-mentioned clinical study. 
My doctor __________________________________ informed me in a 
personal counseling interview about the study drug, possible side effects and 
risks, the nature, objective and significance of this clinical study, and my 
responsibilities resulting thereof, In addition, I read and understood the 
contents of the Patient Information Sheet and the Informed Consent Form.  
The doctor answered all questions in an adequate and comprehensible manner.  
I had sufficient time to decide on my participation in this clinical study. 
I will follow the instructions of my doctor, which are essential for the 
performance of this clinical study.  I have the right to withdraw from the study 
at any time without giving any reason and without any disadvantage for me. 
I confirm that I have not participated in this study and I have not taken part in 
another study within the last 30 days prior to the start of the study. 
I received one original of the Patient Information Sheet together with the 
signed Information Consent Form. 
 
_______________________________________________________________ 
(Place, date and Signature of the patient) 
 
_______________________________________________________________ 
(Place, date and Signature of the doctor) 
 ANNEXURE III 
 
 
PATIENT INFORMATION SHEET 
 
 
Who can be contacted for further questions? 
 
For further questions regarding this clinical study or your rights as patient and 
participant in the study, please contact your doctor, who will always be ready 
to provide you the necessary information. 
 
If you have experienced any health-related problem as well as in case of 
hospitalization please contact your doctor. 
 
Name and address of Contact Person: _______________________________ 
______________________________________________________________ 
Phone Number: ____________________________________ 
Please take a copy of this information sheet home with you. 
 
 ANNEXURE IV 
 
INFORMED CONSENT FORM IN TAMIL 
Nehahspapd; ngah;:_______________  taJ:_______ ,dk;: _________ 
tpyhrk;: _______________________________________________________  
 
jfty; mspf;fg;gl;l x; ; ; ;; ; ; ;; ; ; ; g;Gjy; gbtk;; ; ;; ; ;; ; ; 
 
Nkw;Fwpg;gpl;l kUj;Jt Ma;tpy; Xh; gq;Nfw;ghsuhf Nrh;f;fg;gl ,jd; 
%yk; ehd; Rje;jpukhf vd; Xg;Gjiy mspf;fpNwd;. 
 
Ma;T kUe;J gw;wp xU jdpg;gl;l MNyhrid Neh;Kf tpsf;fj;jpy; vd; 
Ma;T kUj;Jth; Ma;T kUe;J, rhj;jpakhFk; tpisTfs; kw;Wk; 
mghaq;fs,; ,ay;G, ,e;j kUj;Jt Ma;tpd; Nehf;fk; kw;Wk; 
Kf;fpaj;Jtk; gw;wp kw;Wk;  mjdhy; Vw;gLk; vdJ nghWg;Gfs; gw;wp 
vdf;F jfty; njhptpf;fpd;whh;.  ,NjhL $Ljyhf, ehd; 
…………………… Njjpapl;l vdf;F mspf;fg;gl;l Nehahspf;fhd 
jfty; jhs; kw;Wk; jfty; mspf;fg;gl;l xg;Gjy; gbtj;jpy; mlq;fpa 
tpguq;fs; gw;wp gbj;J Ghpe;J nfhz;Ls;Nsd;.  kUj;Jth; Nghjpa kw;Wk; 
tphpthd tpjj;jpy; vd; midj;Jf; Nfs;tpfSf;Fk; gjpy;fs; 
mspj;Js;shh;.  ,e;j kUj;Jt Ma;tpy; vd; gq;Nfw;G gw;wpj; jPh;khdpf;f 
vdf;Fg; Nghjpa Neuk; ,Ue;jJ. 
 
,e;j kUj;Jt Ma;T elj;jg;gl kpf Kf;fpakhdjhf vd; kUj;Jthpd; 
Fwpg;Gfis ehd; gpd;gw;WNtd;.  ve;j fhuzKk; mspf;fhky; , vdf;F 
ve;j e\;lKk; Vw;glhky; ve;j Neuj;jpYk; Ma;it tpl;L tpyf vdf;F 
chpik cz;L. 
 
,e;j kUj;Jt Ma;tpy; Nrfhpf;fg;gLk; vdJ nrhe;j jfty; , Fwpg;ghf 
vdJ kUj;Jt nufhh;Lfspy; vdJ ngah; kw;Wk; ghypdk; kw;Wk; ,dk; 
Fwpf;fg;gLk; vd;gjw;F ehd; rk;kjpf;fpNwd; ,e;j jfty; MdJ 
 
∗ vyf;l;uhdpfy; Kiwapy; my;yJ xU gFjp fhfpj tbtpy; gjpT 
nra;ag;gLk; gj;jpukhf itf;fg;gLk; kw;Wk; kjpg;gPL nra;ag;gLk; 
 
∗ tpQ;Qhd kjpg;gPL kw;Wk; $Ljy; tpQ;Qhd cgNahfj;Jf;fhf 
kw;Wk; mspf;fg;gLk;. 
 
∗ cfe;j Njrpa kw;Wk; rh;tNjr nuFNyl;lhp mjhhpl;bfSf;F 
mDg;gg;gLk;. 
 
.,NjhL kl;Lkpd;wp mq;fPfhpfg;gl;l gpujpepjpfs; vdJ nrhe;j tpguq;fs; 
cldhd kUj;Jt nufhh;Lfis ghpNrhjpf;fyhk;.  tpQ;Qhd kjpg;gPL 
 kw;Wk; kUj;Jt Ma;tpd; nray; jpwDf;fhf jftiy KOikahf 
rhpahfg; ghpkhw;wk; nra;a ,J cjTfpwJ. 
 
ehd; ,e;j Ma;tpy; ,Jtiu gq;Nfw;W ,Uf;ftpy;iy kw;Wk; ,e;j 
Ma;T Muk;gpf;Fk; Kd;G 30 ehl;fspy; ehd; kw;nwhU Ma;tpy; 
gq;Nfw;wpUf;ftpy;iy vd;gij cWjp nra;fpNwd;. 
 
Nehahspf;fhd jfty; jhspd; xU mry; cld; ifnaOj;jplg;gl;l 
jfty; mspf;fg;gl;l xg;Gjy; gbtj;ij ehd; ngw;Ws;Nsd;. 
 
Nehahsp:  
_____________________    ____________ __________________      
 
ngah; nghpa vOj;Jf;fspy;   ifnaOj;J     Njjp 
 
rhl;rp:  
_____________________    ____________ __________________      
ngah; nghpa vOj;Jf;fspy;     ifnaOj;J      Njjp 
Nehahspf;F cwT Kiw: _______________________________ 
ehd; lhf;lh; ………………… Nkw;fz;l ngaUila Nehahspf;F 
Ma;tpd; Nehf;fk; kw;Wk; jd;ik gw;wp tpsf;fpAs;Nsd; vd;gij cWjp 
nra;fpNwd;.  NkYk; ehd; midj;J Ma;T rk;ge;jg;gl;l Nfs;tpfSf;Fk; 
gjpy;fs; mspj;Js;Nsd;. kw;Wk; Ma;tpd; epge;jidfis (kw;Wk; 
Vw;glyhk; vDk; tpisTfs;) mth;fSf;F tpsf;fpAs;Nsd; vd;gij 
cWjp nra;fpNwd;. 
kUj;Jth; lhf;lh;:  
________________________    _____________          ___________________ 
ngah; nghpa vOj;Jf;fspy;   ifnaOj;J        Njjp 
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(fhy; rij gw;wp 
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3. H/o. Palpitation 
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6. Insomnia, Restlessness 
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7. Any Other 
(NtW VNjDk; cly; 
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Njhd;wpdhy; vOjTk;) 
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